Skip to main content

Now on MedTalks

Dr. Tarantino sits down with Team Novo8™ member Tammy Davenport to put women with hemophilia in the spotlight. Tune in to hear them discuss the need for better comprehensive care and treatment options for female patients and how they're raising awareness.

Please see full Prescribing Information.

Individual results may vary.

Play
Pause
Skip
Volume
Chapters
Transcript
References
Subtitles
Fullscreen

Now on MedTalks

Chapters
Transcript
References

Dr. Tarantino sits down with Team Novo8™ member Tammy Davenport to put women with hemophilia in the spotlight. Tune in to hear them discuss the need for better comprehensive care and treatment options for female patients and how they're raising awareness.

Please see full Prescribing Information.

Individual results may vary.

Return to overview

Transcripts

Return to overview

References


Selected Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment

Indications and Usage

Novoeight® (antihemophilic factor, recombinant) is indicated for use in adults and children with hemophilia A for on-demand treatment and control of bleeding episodes, perioperative management, and routine prophylaxis to reduce the frequency of bleeding episodes.

  • Novoeight® is not indicated for the treatment of von Willebrand disease

Important Safety Information

Contraindications

  • Do not use in patients who have had life-threatening hypersensitivity reactions, including anaphylaxis, to Novoeight® or its components, including hamster proteins

Warnings and Precautions

  • Anaphylaxis and severe hypersensitivity reactions are possible. Patients may develop hypersensitivity to hamster proteins, which are present in trace amounts in the product. Should symptoms occur, discontinue Novoeight® and administer appropriate treatment
  • Development of activity-neutralizing antibodies (inhibitors) may occur. Previously untreated patients (PUPs) are at greatest risk for inhibitor development with all factor VIII products. Inhibitors have been reported following administration of Novoeight in PUPs. If expected plasma factor VIII activity levels are not attained, or if bleeding is not controlled with an appropriate dose, perform testing for factor VIII inhibitors

Adverse Reactions

  • The most frequently reported adverse reactions (≥1%) were inhibitors in Previously Untreated Patients (PUPs), injection site reactions, and pyrexia.

Please click here for Prescribing Information.